LOUISVILLE, CO ANTB, (Marketwired July 17, 2017) AntriaBio, Inc. ( AntriaBio or the Company ) (OTCQB: ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with diabetes and metabolic diseases, announced today that it has closed on a total of $13 million as part of a planned private placement transaction. Under the terms of the financing, accredited investors paid $1.00 for one share of common stock. The amount raised to date includes investments made
http://bit.ly/2vuRSMc
No comments:
Post a Comment